Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is a growing concern in the modern world. As the currently available medications are not very promising, there is an increased need for the fabrication of newer drugs. Curcumin is a plant derived compound which has potential activities beneficial for the treatment of Alzheimer's disease. Anti-amyloid activity and anti-oxidant activity of curcumin is highly beneficial for the treatment of Alzheimer's disease. The insolubility of curcumin in water restricts its use to a great extend, which can be overcome by the synthesis of curcumin nanoparticles. In our work, we have successfully synthesized water-soluble PLGA coated- curcumin nanoparticles and characterized it using different techniques. As drug targeting to diseases of cerebral origin are difficult due to the stringency of blood-brain barrier, we have coupled the nanoparticle with Tet-1 peptide, which has the affinity to neurons and possess retrograde transportation properties. Our results suggest that curcumin encapsulated-PLGA nanoparticles are able to destroy amyloid aggregates, exhibit anti-oxidative property and are non-cytotoxic. The encapsulation of the curcumin in PLGA does not destroy its inherent properties and so, the PLGA-curcumin nanoparticles can be used as a drug with multiple functions in treating Alzheimer's disease proving it to be a potential therapeutic tool against this dreaded disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Anand, P., Nair, H. B., Sung, B., Kunnumakkara, A. B., Yadav, V. R., Tekmal, R. R., & Aggarwal, B. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.003 · Cited by 574
RetractedBioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 2×
“Three different Phase I clinical trials have proven that curcumin is safe at high doses (12 g/day) [19].”
BackgroundBiodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 4×
“, [9] and Ono et al.”
BackgroundInfluentialCurcumin as “Curecumin”: From kitchen to clinic
Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.016 · Cited by 2,214
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181 · cited 1×
“clathrin-mediated endocytosis [37].”
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., & Maitra, A. (2007) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-5-3 · Cited by 1,090
Cited by
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Nair, S., Bhatnagar, P., Karmakar, M., Kumari, M., Chauhan, L. K. S., Patel, D. K., et al. (2014) · ACS Nano · doi:10.1021/nn405077y · Cited by 558
“Flow cytometry was carried out to study the cellular uptake of FITC-tagged CurPLGA-NPs (FITC-Cur-PLGA-NPs) following an earlier published method.(83) In brief, hippocampus-derived NSC were treated with FITC-Cur-PLGA-NPs and empty PLGA-NPs for 6 h.”
MethodDrug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Biopolymer nano-particles and natural nano-carriers for nano-encapsulation of phenolic compounds
Faridi Esfanjani, A., & Jafari, S. M. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2016.06.053 · Cited by 544
Lee, W.-H., Loo, C.-Y., Bebawy, M., Luk, F., Mason, R., & Rohanizadeh, R. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040002 · Cited by 537
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
Nanocurcumin: A Promising Candidate for Therapeutic Applications
Karthikeyan, A., Senthil, N., & Min, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00487 · Cited by 414
Curcumin: An age-old anti-inflammatory and anti-neoplastic agent
Fadus, M. C., Lau, C., Bikhchandani, J., & Lynch, H. T. (2017) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2016.08.002 · Cited by 318
Cheng, K. K., Yeung, C. F., Ho, S. W., Chow, S. F., Chow, A. H. L., & Baum, L. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9444-4 · Cited by 314
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Application of different nanocarriers for encapsulation of curcumin
Rafiee, Z., Nejatian, M., Daeihamed, M., & Jafari, S. M. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1495174 · Cited by 300
Polyphenols and Their Impact on the Prevention of Neurodegenerative Diseases and Development
Grabska-Kobyłecka, I., Szpakowski, P., Król, A., Książek-Winiarek, D., Kobyłecki, A., Głąbiński, A., & Nowak, D. (2023) · Nutrients · doi:10.3390/nu15153454 · Cited by 273
Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 259
Fan, S., Zheng, Y., Liu, X., Fang, W., Chen, X., Liao, W., Jing, X., Lei, M., Tao, E., Ma, Q., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1461955 · Cited by 258
Critical evaluation of biodegradable polymers used in nanodrugs
Caballero-George, C., Marin, & Briceño (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47186 · Cited by 252
Formulations of Curcumin Nanoparticles for Brain Diseases
Del Prado-Audelo, M. L., Caballero-Florán, I. H., Meza-Toledo, J. A., Mendoza-Muñoz, N., González-Torres, M., Florán, B., Cortés, H., & Leyva-Gómez, G. (2019) · Biomolecules · doi:10.3390/biom9020056 · Cited by 191
“PLGA Tet-1 150-200, Ψ = −30 to −20 Amyloid aggregates (in vitro model) [107]”
BackgroundNose-To-Brain Delivery of PLGA-Diazepam Nanoparticles
Sharma, D., Sharma, R. K., Sharma, N., Gabrani, R., Sharma, S. K., Ali, J., & Dang, S. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-015-0294-0 · Cited by 127
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Mehla, J., Gupta, P., Pahuja, M., Diwan, D., & Diksha, D. (2020) · Brain Sciences · doi:10.3390/brainsci10120964 · Cited by 108
“These nanoparticles were found to be able to destroy amyloid aggregation and exhibit antioxidative activity without a cytotoxic effect [99,100].”
BackgroundLeyva-Gómez, G., Cortés, H., Magaña, J. J., Leyva-García, N., Quintanar-Guerrero, D., & Florán, B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.009 · Cited by 102
Personalized nanomedicine for CNS diseases
Kaushik, A., Jayant, R. D., Bhardwaj, V., & Nair, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.010 · Cited by 95
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Del Amo, L., Cano, A., Ettcheto, M., Souto, E. B., Espina, M., Camins, A., García, M. L., & Sánchez-López, E. (2021) · Applied Sciences · doi:10.3390/app11094305 · Cited by 67
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
“62 More recently, Saleh et al engineered Tet-1-PLGA platforms to deliver small flavonoids like berberine and isoflavones, which alleviated tau pathology and cognitive deficits in AD models.”
Derakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48
Gupta, P. K., Pappuru, S., Gupta, S., Patra, B., Chakraborty, D., & Verma, R. S. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.03.041 · Cited by 44
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Gupta, P. K., Tripathi, S. K., Pappuru, S., Chabattula, S. C., Govarthanan, K., Gupta, S., Biswal, B. K., Chakraborty, D., & Verma, R. S. (2020) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.110285 · Cited by 29
New biologicals and biomaterials in the therapy of Alzheimer's disease
Prajapati, V., Shinde, S., Shrivastav, P., & Prajapati, B. G. (2024) · Alzheimer's Disease and Advanced Drug Delivery Strategies · doi:10.1016/b978-0-443-13205-6.00016-9 · Cited by 7
Metadata
- Authors
- Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., & Kumar, D. S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-05
- Volume
- 7
- Issue
- 3
- Pages
- e32616
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2055928970
- Cited by
- 442
- References
- 42
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.